Acquired resistance to ivosidenib has been best studied in AML, where secondary IDH1 mutations, isoform switching via the acquisition of oncogenic IDH2 mutations, and the emergence of mutations in TET2 and the MAPK pathway have been described17–19. This evidence concerns the gene IDH2 and acute myeloid leukemia.